{"id":754933,"date":"2023-05-04T09:52:21","date_gmt":"2023-05-04T13:52:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/"},"modified":"2023-05-04T09:52:21","modified_gmt":"2023-05-04T13:52:21","slug":"theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/","title":{"rendered":"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ROCKVILLE, Md., May  04, 2023  (GLOBE NEWSWIRE) &#8212; Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, May 11, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide a corporate update.<\/p>\n<p align=\"justify\">Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13738367. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call via the \u201cNews &amp; Media\u201d section of the company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uHfoedCLfmkqynY6XFh2gKjr0aR_NSleuz0n9Q6D8z7bmEmU6xl2xNTT5cnuSorcUAp08k683q4igGPAWSv3LN89qSKz9xh6mAOEWK0oNKE=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.therivabio.com<\/a>, under \u201cEvents\u201d or by clicking <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SL6uNYdyJmuNs2YYFJNNTpnOK9MhLA74EvXdyODPbSb-05qFCWVciLMHwcKuq0tVn2au2UWWdjZPhcwvV0XXi3eKydY2dHXg_pNn9_fJ2VF-KUdDOz7b-I3IN6Kk_AGA\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>, up to 90 days after the call.<\/p>\n<p align=\"justify\">\n        <strong>About Theriva Biologics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company\u2019s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient\u2019s immune system. The Company\u2019s lead clinical-stage candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9PNa24mVL5GmaIOI4NPJGkoFx_6f9KgOVki1nfT6sBcJKA051tDzr44IjEL5n0750gdJqWPtUY-EZe1qzImTlJNkzmrTNEjZBHFG2puBImc=\" rel=\"nofollow noopener\" target=\"_blank\">www.therivabio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong><br \/>\n        <br \/>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Chris Calabrese<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jv5qb242cFpJ804H16hlq7G9puTRND4g8kQfgum7U1wzNS-Mj1aZxVvwGzWSZo0CFswV_mLPYhOE8VFVKjpLGoGWU0bKJcaS2TEUgMm5a7zwtSkRES7W1yAMvEQsP6jM\" rel=\"nofollow noopener\" target=\"_blank\">ccalabrese@lifesciadvisors.com<br \/><\/a>917-680-5608<\/p>\n<p align=\"justify\">Source: Theriva Biologics, Inc.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YWJkYjFhN2ItYjRiMC00MDQwLWJmZTYtZDIwNjU0NTIzNTRkLTUwMDEwMTU4MQ==\/tiny\/Theriva-Biologics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, May 11, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13738367. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754933","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, May 11, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13738367. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call &hellip; Continue reading &quot;Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T13:52:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results\",\"datePublished\":\"2023-05-04T13:52:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/\"},\"wordCount\":390,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/\",\"name\":\"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==\",\"datePublished\":\"2023-05-04T13:52:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results - Market Newsdesk","og_description":"ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, May 11, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13738367. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call &hellip; Continue reading \"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T13:52:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results","datePublished":"2023-05-04T13:52:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/"},"wordCount":390,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/","name":"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==","datePublished":"2023-05-04T13:52:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDE5OSM1NTcwMjQ3IzUwMDEwMTU4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-host-conference-call-and-webcast-to-discuss-first-quarter-2023-operational-highlights-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754933"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754933\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}